Allergan plc (AGN) Tanks 21 Percent On Treasury Inversion Announcement
What a market! Allergan plc (AGN) is getting absolutely KILLED in after hours trading. Not sure I remember such a big down move in a big cap pharma since the recent declines in Valeant. Allergan is currently down about 21 percent to $219.90 in after hours trading on news that the Treasury plans to crack down on tax inversions. The announcement could be aimed at preventing transactions like the Pfizer bid to acquire Allergan (announced in November 2015), which many believe is being done largely for tax purposes. On the other hand, shares of Pfizer are up about 2.3 percent in after hours sessions. Allergan is not mentioned by name but sometimes these matters are obvious. Anyway, we will have much more on the topic tomorrow for now see below.
Allergan plc bloody Monday
Releases Updated Framework for Business Tax Reform as Model for Future Action
WASHINGTON – Today, the U.S. Department of the Treasury and the Internal Revenue Service (IRS) issued temporary and proposed regulations to further reduce the benefits of and limit the number of corporate tax inversions, including by addressing earnings stripping. By undertaking an inversion transaction, companies move their tax residence overseas to avoid U.S. taxes without making significant changes in their business operations. After an inversion, many of these companies continue to take advantage of the benefits of being based in the United States, while shifting a greater tax burden to other businesses and American families.
“Treasury has taken action twice to make it harder for companies to invert. These actions took away some of the economic benefits of inverting and helped slow the pace of these transactions, but we know companies will continue to seek new and creative ways to relocate their tax residence to avoid paying taxes here at home,” said Treasury Secretary Jacob J. Lew. “Today, we are announcing additional actions to further rein in inversions and reduce the ability of companies to avoid taxes through earnings stripping. This will have an important effect, but we cannot stop these transactions without new legislation. I urge Congress to move forward with anti-inversion legislation this year. Ultimately, the best way to address inversions is to reform our business tax system, which is why Treasury is releasing anupdated framework on business tax reform, outlining the administration’s proposals to date as a guide for future reform. While that work goes on, Congress should not wait to act as inversions continue to erode our tax base.”
Genuine cross-border mergers make the U.S. economy stronger by enabling U.S. companies to invest overseas and encouraging foreign investment to flow into the United States. But these transactions should be driven by genuine business strategies and economic efficiencies, not a desire to shift the tax residence of a parent entity to a low-tax jurisdiction simply to avoid U.S. taxes.
Today, Treasury is taking action to:
·Limit inversions by disregarding foreign parent stock attributable to recent inversions or acquisitions of U.S. companies. This will prevent a foreign company (including a recent inverter) that acquires multiple American companies in stock-based transactions from using the resulting increase in size to avoid the current inversion thresholds for a subsequent U.S. acquisition.
·Address earnings stripping by:
o Targeting transactions that generate large interest deductions by simply increasing related-party debt without financing new investment in the United States.
o Allowing the IRS on audit to divide debt instruments into part debt and part equity, rather than the current system that generally treats them as wholly one or the other.
o Facilitating improved due diligence and compliance by requiring certain large corporations to do up-front due diligence and documentation with respect to the characterization of related-party financial instruments as debt. If these requirements are not met, instruments will be treated as equity for tax purposes.